Pembrolizumab and ATRA for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two medicines, pembrolizumab and ATRA (a form of vitamin A), for people with certain lymphomas that have come back or stopped responding to earlier treatments. The goal is to see if the combination can help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Hodgkin lymphoma that came back after one prior treatment, or a B-cell non-Hodgkin lymphoma that came back after two prior treatments, or primary mediastinal large B-cell lymphoma that did not respond to first therapy.
- You are able to do most daily activities (ECOG score 0, 1, or 2).
- You have not received a therapy that targets PD-1 or PD-L1 (like pembrolizumab) before.
- Your kidney and liver function are adequate for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
Hear when a new Refractory Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.